metaEvidence - overview


			deaths (OS)
mML - NA - all population metastatic/adv melanoma (mML) mML - (neo)adjuvant (NA) mML - NA - all population
versus nivolumab alone
	nivolumab plus ipilimumab vs. nivolumab alone	1	-
versus placebo
	nivolumab plus ipilimumab vs. placebo	1	-
mML - NA - PDL1 positive metastatic/adv melanoma (mML) mML - (neo)adjuvant (NA) mML - NA - PDL1 positive
mML - L1 - all population metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - all population
versus ipilimumab alone
	nivolumab plus ipilimumab vs. ipilimumab alone	2	NaN [NaN; NaN] /10000 0/0 vs. 0/0
versus nivolumab alone
	nivolumab plus ipilimumab vs. nivolumab alone	1	NaN [NaN; NaN] /10000 0/0 vs. 0/0
mML - L1 - BRAF mutant metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF mutant
versus ipilimumab alone
	nivolumab plus ipilimumab vs. ipilimumab alone	1	1217 [-2442; 4876] /10000 12/23 vs. 4/10
mML - L1 - BRAF wild metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF wild
versus ipilimumab alone
	nivolumab plus ipilimumab vs. ipilimumab alone	1	-
mML - L2 - all population metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - all population
mML - L2 - BRAF mutant metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - BRAF mutant